Harley-Davidson (HOG) Stock Rating Maintained at Wedbush; The $49.0 Target Indicates -3.52% Potential; Celldex Therapeutics (CLDX) Sellers Increased By 1.14% Their Shorts

December 7, 2017 - By Darrin Black

Among 25 analysts covering Harley-Davidson (NYSE:HOG), 5 have Buy rating, 1 Sell and 19 Hold. Therefore 20% are positive. Harley-Davidson has $78 highest and $40 lowest target. $52.91’s average target is 4.17% above currents $50.79 stock price. Harley-Davidson had 81 analyst reports since July 22, 2015 according to SRatingsIntel. The rating was downgraded by Goldman Sachs to “Neutral” on Monday, June 6. The firm has “Buy” rating by Stifel Nicolaus given on Tuesday, October 13. On Thursday, September 15 the stock rating was maintained by UBS with “Neutral”. The company was maintained on Thursday, July 13 by BMO Capital Markets. The firm earned “Sector Perform” rating on Wednesday, February 1 by RBC Capital Markets. The firm has “Neutral” rating by Wedbush given on Wednesday, April 19. The firm has “Sector Perform” rating by RBC Capital Markets given on Friday, January 29. The stock has “Hold” rating by Zacks on Thursday, August 20. UBS downgraded the shares of HOG in report on Wednesday, July 6 to “Neutral” rating. The rating was downgraded by BMO Capital Markets to “Market Perform” on Wednesday, October 21.

Celldex Therapeutics Incorporated (NASDAQ:CLDX) had an increase of 1.14% in short interest. CLDX’s SI was 7.41 million shares in December as released by FINRA. Its up 1.14% from 7.32 million shares previously. With 1.30M avg volume, 6 days are for Celldex Therapeutics Incorporated (NASDAQ:CLDX)’s short sellers to cover CLDX’s short positions. The SI to Celldex Therapeutics Incorporated’s float is 6.39%. The stock increased 4.20% or $0.12 during the last trading session, reaching $2.98. About 339,051 shares traded. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has declined 20.62% since December 7, 2016 and is downtrending. It has underperformed by 37.32% the S&P500.




Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company has market cap of $405.24 million. The Company’s drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It currently has negative earnings. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers.

Among 13 analysts covering Celldex Therapeutics (NASDAQ:CLDX), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. Celldex Therapeutics had 24 analyst reports since August 11, 2015 according to SRatingsIntel. WBB Securities maintained it with “Buy” rating and $10.0 target in Wednesday, December 6 report. H.C. Wainwright maintained Celldex Therapeutics, Inc. (NASDAQ:CLDX) rating on Tuesday, March 8. H.C. Wainwright has “Buy” rating and $6 target. Cantor Fitzgerald maintained Celldex Therapeutics, Inc. (NASDAQ:CLDX) rating on Friday, February 26. Cantor Fitzgerald has “Buy” rating and $25 target. The stock has “Neutral” rating by Wedbush on Monday, March 7. Leerink Swann downgraded the shares of CLDX in report on Monday, March 7 to “Market Perform” rating. TH Capital maintained the shares of CLDX in report on Tuesday, August 11 with “Buy” rating. Jefferies downgraded Celldex Therapeutics, Inc. (NASDAQ:CLDX) on Tuesday, March 8 to “Hold” rating. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) has “Hold” rating given on Tuesday, August 9 by Jefferies. Guggenheim downgraded Celldex Therapeutics, Inc. (NASDAQ:CLDX) on Monday, March 7 to “Neutral” rating. The rating was maintained by Brean Capital on Tuesday, August 11 with “Buy”.

Investors sentiment decreased to 0.91 in 2017 Q2. Its down 0.09, from 1 in 2017Q1. It dropped, as 52 investors sold Harley-Davidson, Inc. shares while 157 reduced holdings. 53 funds opened positions while 137 raised stakes. 153.33 million shares or 4.67% more from 146.48 million shares in 2017Q1 were reported. Impala Asset Management Limited Com owns 2.08 million shares for 5.69% of their portfolio. Moreover, Weik Inv Serv Inc has 0.5% invested in Harley-Davidson, Inc. (NYSE:HOG) for 17,500 shares. Qs Invsts Ltd Limited Liability Company holds 2,400 shares or 0% of its portfolio. 77,060 were reported by Brown Advisory. Bedrijfstakpensioenfonds Voor De Media Pno reported 0.13% stake. Cambiar Limited Liability Company invested in 0.05% or 62,472 shares. Arrow Fincl Corporation, a New York-based fund reported 1,075 shares. Comerica Bank & Trust holds 0.02% or 50,962 shares. Bartlett And Lc holds 0.01% of its portfolio in Harley-Davidson, Inc. (NYSE:HOG) for 5,995 shares. Sg Americas Securities Limited Co reported 11,041 shares. Fjarde Ap reported 43,482 shares stake. Pathstone Family Office Llc has 0% invested in Harley-Davidson, Inc. (NYSE:HOG). South Dakota Investment Council reported 56,300 shares. Leavell Investment Mngmt Incorporated has invested 0.04% of its portfolio in Harley-Davidson, Inc. (NYSE:HOG). Apg Asset Mgmt Nv reported 0.01% stake.

Analysts await Harley-Davidson, Inc. (NYSE:HOG) to report earnings on January, 30. They expect $0.47 earnings per share, up 74.07% or $0.20 from last year’s $0.27 per share. HOG’s profit will be $78.45 million for 27.02 P/E if the $0.47 EPS becomes a reality. After $0.40 actual earnings per share reported by Harley-Davidson, Inc. for the previous quarter, Wall Street now forecasts 17.50% EPS growth.

Harley-Davidson, Inc. primarily manufactures and sells cruiser and touring motorcycles. The company has market cap of $8.48 billion. The firm operates through two divisions, Motorcycles & Related Products, and Financial Services. It has a 15.85 P/E ratio. The Motorcycles & Related Products segment designs, makes, and sells wholesale on-road Harley-Davidson motorcycles, as well as motorcycle parts, accessories, general merchandise, and related services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: